Source comparison
Receptor Pathways: GHRH vs Ghrelin Mimetics
Tesamorelin's activity centers on the GHRH receptor (GHRHR), a G-protein-coupled receptor expressed on somatotroph cells in the anterior pituitary. When tesamorelin binds GHRHR, it triggers cyclic AMP (cAMP) production, which activates protein kinase A (PKA) a
This comparison does not assign a generated winner or score.
- Tesamorelin's activity centers on the GHRH receptor (GHRHR), a G-protein-coupled receptor expressed on somatotroph cells in the anterior pituitary. When tesamorelin binds GHRHR, it triggers cyclic AMP (cAMP) production, which activates protein kinase A (PKA) and ultimately stimulates transcription of the GH gene. The result is sustained GH secretion for 2–4 hours post-administration, with peak plasma GH concentrations occurring 30–90 minutes after subcutaneous injection. This mechanism is identical to endogenous GHRH. Tesamorelin is simply a stabilized analogue with a longer half-life (43 minutes versus 7 minutes for native GHRH).
- Ipamorelin, in contrast, binds the ghrelin receptor (GHSR-1a). A completely separate pathway. GHSR-1a activation also triggers cAMP production and PKA activation, but the receptor distribution differs: GHSR-1a is expressed not only in the pituitary but also in the hypothalamus, hippocampus, and gastrointestinal tract. Ipamorelin's selectivity lies in its failure to activate ACTH or prolactin secretion, which distinguishes it from older secretagogues like GHRP-2 and GHRP-6. The clinical advantage is that ipamorelin produces a GH pulse (peak at 20–40 minutes, return to baseline by 90 minutes) without cortisol elevation or appetite stimulation. Side effects that would compound negatively when stacking peptides.
- Our experience with dual-pathway protocols shows that timing the administration determines whether the pathways synergize or interfere. Administering both compounds simultaneously creates overlapping GH peaks that exceed physiological ranges and may trigger negative feedback through IGF-1 suppression of GHRH release. The preferred protocol administers tesamorelin in the morning (to align with the natural cortisol peak, which would otherwise blunt GH response) and ipamorelin 4–6 hours later or before bed (to leverage the endogenous nocturnal GH pulse). This spacing preserves pulsatility while extending the daily GH elevation window.